Shenzhen New Industries Biomedical Engineering (300832.SZ) Earnings Analysis

Shenzhen New Industries Biomedical Engineering (300832.SZ) next reports earnings on 2026-08-14, consensus EPS 0.4956 CNY. Last quarter (2025-09-29) it beat with EPS 0.552 CNY vs 0.551 CNY est (+0.2%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E 23.14.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 300832.SZ next report earnings?

Next earnings date2026-08-14
Consensus EPS estimate0.4956 CNY
Revenue estimate1.25B

300832.SZ earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2025-09-290.552 CNY0.551 CNY+0.2%Beat
2025-08-250.4179 CNY0.565 CNY-26%Miss
2025-04-250.56 CNY0.585 CNY-4.3%Miss
2024-12-310.566 CNYn/an/an/a
2024-10-280.61 CNY0.7 CNY-12.9%Miss
2024-08-220.61 CNY0.6 CNY+1.7%Beat

Beat rate: 2/5 (40%) over reported quarters with consensus data.

300832.SZ valuation and analyst view

Trailing P/E23.14
Trailing EPS2.068 CNY
Price / book3.95
Dividend yield2.52%
Market cap38.05B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Shenzhen New Industries Biomedical Engineering (300832.SZ)'s next earnings date?

Shenzhen New Industries Biomedical Engineering is next scheduled to report on 2026-08-14, with a consensus EPS estimate of 0.4956 CNY and revenue estimate of 1.25B.

Did 300832.SZ beat earnings last quarter?

In its 2025-09-29 report, 300832.SZ posted EPS of 0.552 CNY versus a 0.551 CNY estimate — a beat of 0.2%.

What is 300832.SZ's earnings track record?

Over the last 5 reported quarters with consensus data, 300832.SZ beat estimates 2 times (40%).

What is 300832.SZ's current P/E ratio and EPS?

300832.SZ trades at a trailing P/E of 23.14 on trailing EPS of 2.067713783918772 CNY.

What do analysts rate 300832.SZ?

300832.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.